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downstream of the source element, in a process called 3′ transduc-
tion7–9. L1 retrotransposons can also promote the somatic trans-
mobilization of Alu elements, SINE-VNTR-Alu (SVA) elements 
and processed pseudogenes, which are copies of mRNAs that have 
been reverse transcribed into DNA and inserted into the genome 
with the machinery of active L1 elements10–12.
Approximately 50% of human tumors contain somatic ret-
rotranspositions of L1 elements7,13–15. Previous analyses indicate that 
although a fraction of somatically acquired L1 insertions in cancer 
may influence gene function, the majority of retrotransposon inte-
grations in a single tumor represent passenger mutations with little 
or no effect on cancer development7,13. Nonetheless, L1 elements are 
capable of promoting other types of genomic structural alterations 
in the germline and somatically, in addition to canonical L1 inser-
tion events16–18; the effect of these alterations remains largely unex-
plored in the context of human cancer19,20.
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About half of all cancers have somatic integrations of retrotransposons. Here, to characterize their role in oncogenesis, we 
analyzed the patterns and mechanisms of somatic retrotransposition in 2,954 cancer genomes from 38 histological cancer sub-
types within the framework of the Pan-Cancer Analysis of Whole Genomes (PCAWG) project. We identified 19,166 somatically 
acquired retrotransposition events, which affected 35% of samples and spanned a range of event types. Long interspersed 
nuclear element (LINE-1; L1 hereafter) insertions emerged as the first most frequent type of somatic structural variation in 
esophageal adenocarcinoma, and the second most frequent in head-and-neck and colorectal cancers. Aberrant L1 integrations 
can delete megabase-scale regions of a chromosome, which sometimes leads to the removal of tumor-suppressor genes, and 
can induce complex translocations and large-scale duplications. Somatic retrotranspositions can also initiate breakage–fusion–
bridge cycles, leading to high-level amplification of oncogenes. These observations illuminate a relevant role of L1 retrotrans-
position in remodeling the cancer genome, with potential implications for the development of human tumors.
L1 retrotransposons are widespread repetitive elements in the human genome, representing 17% of the entire DNA con-tent1,2. Using a combination of cellular enzymes and self-
encoded proteins with endonuclease and reverse transcriptase 
activity, L1 elements copy and insert themselves at new genomic 
sites, in a process called retrotransposition. Most of the approxi-
mately 500,000 L1 copies in the human reference genome are trun-
cated, inactive elements that are unable to retrotranspose. A small 
subset of them, around 100–150 L1 loci, remain active in the aver-
age human genome, acting as source elements, a small number of 
which consists of highly active copies termed hot-L1s3–5. These L1 
source elements are usually transcriptionally repressed, but epigen-
etic changes that occur in tumors may promote their expression 
and allow them to retrotranspose6,7. Somatic L1 retrotransposition 
usually introduces a new copy of the 3′ end of the L1 sequence, 
and can also mobilize unique DNA sequences located immediately 
A full list of authors and affiliations appears at the end of the paper.
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To further understand the roles of retrotransposons in cancer, 
we developed strategies to analyze the patterns and mechanisms of 
somatic retrotransposition in 2,954 cancer genomes from 38 his-
tological cancer subtypes within the framework of the PCAWG 
project21, many of which had not been evaluated for retrotransposi-
tion. On the basis of the robustness of the retrotransposition calls, 
we retained 296 tumors that were preliminarily excluded by the 
PCAWG Consortium21 (see Methods). Our analyses identify pat-
terns and mutational mechanisms of structural variation in human 
cancers that are mediated by L1 retrotransposition. We found that 
the aberrant integration of L1 retrotransposons has a relevant role in 
remodeling the architecture of the cancer genome in some human 
tumors, mainly by promoting megabase-scale deletions that, occa-
sionally, generate genomic consequences that may promote can-
cer development through the removal of tumor-suppressor genes, 
such as CDKN2A, or trigger the amplification of oncogenes, such 
as CCND1.
Results
The landscape of somatic retrotransposition in a large can-
cer whole-genome dataset. We ran our bioinformatic pipelines 
(Methods and Supplementary Note) to explore somatic retrotrans-
position on whole-genome sequencing data from 2,954 tumors and 
their matched normal pairs, across 38 cancer types (Supplementary 
Fig. 1 and Supplementary Table 1). The analysis retrieved a total of 
19,166 somatically acquired retrotranspositions that were classified 
into six categories (Fig. 1a and Supplementary Table 2). Comprising 
98% (18,739 out of 19,166) of the events, L1 integrations (14,967 
solo-L1, 3,669 L1-transductions, and 103 L1-mediated rearrange-
ments, which mainly comprised deletions) overwhelmingly domi-
nate the landscape of somatic retrotransposition in the PCAWG 
dataset (Fig. 1a,b). By contrast, elements of the lineages Alu 
(Supplementary Fig. 2) and SVA (comprising 130 and 23 somatic 
copies, respectively) and processed pseudogenes, with 274 events, 
represent minor categories.
The core pipeline, TraFiC-mem (Supplementary Fig. 3)—which 
was used to explore somatic retrotransposition in PCAWG—was 
validated by single-molecule whole-genome sequencing data anal-
ysis of one cancer cell line with high retrotransposition rate and 
its matched normal sample, confirming the somatic acquisition of 
295 out of 308 retrotransposition events (false discovery rate <5%, 
Supplementary Fig. 4a,b). To further evaluate TraFiC-mem, we 
reanalyzed a mock cancer genome into which we had previously7 
seeded somatic retrotransposition events at different levels of 
tumor clonality, and then simulated sequencing reads to the aver-
age level of coverage of the PCAWG dataset. The results confirmed 
a high precision (>99%) of TraFiC-mem, and a recall ranging 
from 90 to 94% for tumor clonalities from 25 to 100%, respectively 
(Supplementary Fig. 4c–e).
We observed marked variation in the retrotransposition rate 
across PCAWG tumor types (Fig. 1c and Supplementary Table 3). 
Overall, 35% (1,046 out of 2,954) of all cancer genomes have at 
least one retrotransposition event. However, esophageal adenocar-
cinoma, head-and-neck squamous carcinoma, lung squamous car-
cinoma and colorectal adenocarcinoma are significantly enriched 
in somatic retrotranspositions (Mann–Whitney U-test, P < 0.05; 
Fig. 1c,d and Supplementary Fig. 5). These four tumor types alone 
account for 70% (13,373 out of 19,166) of all somatic events in the 
PCAWG dataset, although they represent just 9% (266 out of 2,954) 
of the samples. This is particularly noticeable in esophageal adeno-
carcinoma, in which 27% (27 out of 99) of the samples show more 
than 100 separate somatic retrotranspositions (Fig. 1c), making L1 
insertions the most frequent type of structural variation in esopha-
geal adenocarcinoma (Fig. 1e). Furthermore, retrotranspositions 
are the second-most frequent type of structural variants in head-
and-neck squamous and colorectal adenocarcinomas (Fig. 1e). 
To gain insights into the genetic causes that make some cancers more 
prone to retrotransposition than others, we looked for associations 
between retrotransposition and driver mutations in cancer-related 
genes. This analysis revealed an increased L1 retrotransposition rate 
in tumors with TP53 mutations (Mann–Whitney U-test, P < 0.05; 
Supplementary Fig. 6), and supports previous analyses that have 
suggested that TP53 functions to restrain mobile elements22,23. We 
also observe a widespread correlation between L1 retrotransposi-
tion and other types of structural variation (Spearman’s ρ = 0.44, 
P < 0.01; Supplementary Fig. 7), a finding that is most likely a 
consequence of a confounding effect of TP53-mutated genotypes 
(Supplementary Fig. 6).
We identified 43% (7,979 out of 18,636) somatic retrotrans-
positions of L1 inserted within gene regions including promot-
ers, of which 66 events hit cancer-associated genes. The analysis 
of expression levels in samples with available transcriptome data, 
revealed four genes—including the ABL oncogene—with L1 
retrotranspositions in the proximity of promoter regions that 
showed significant overexpression compared with the expression 
in the remaining samples of the same tumor type (Student’s t-test, 
q < 0.10; Supplementary Fig. 8a–c). The structural analysis of RNA-
sequencing data identified instances in which portions of a somatic 
retrotransposition within a gene exonize, a process that sometimes 
involves cancer-associated genes (Supplementary Fig. 8d). In addi-
tion, we found evidence of aberrant fusion transcripts arising from 
the inclusion of processed pseudogenes in the target host gene and 
expression of processed pseudogenes landing in intergenic regions 
(Supplementary Fig. 8e).
Dissecting the genomic features that influence the landscape of 
L1 retrotranspositions in cancer. The genome-wide analysis of 
the distribution of somatic L1 insertions across the cancer genome 
revealed considerable variation in the rate of L1 retrotransposi-
tion (Fig. 2a and Supplementary Table 4). To understand the rea-
sons behind such variation, we studied the association of L1 event 
rates with various genomic features. We first investigated whether 
the distribution of somatic L1s across the cancer genome could 
be determined by the occurrence of L1-endonuclease target-site 
motifs. We used a statistical approach based on negative binomial 
regression to deconvolute the influence of multiple overlapping 
genomic variables24; this analysis showed that close matches to 
the motif have a 244-fold increased L1 rate, compared with non-
matched motifs (Fig. 2b and Supplementary Fig. 9a). Adjusting 
for this effect, we found a strong association with DNA replica-
tion time; the latest-replicating quarter of the genome was 8.9-
fold enriched in L1 events (95% confidence interval, 8.25–9.71) 
compared with the earliest-replicating quarter (Fig. 2b,c and 
Supplementary Fig. 9b). Recent work25 has shown that L1 ret-
rotransposition has a strong cell-cycle bias, and preferentially 
occurs during S phase. Our results are in agreement with these 
findings and suggest that L1 retrotransposition peaks in the later 
stages of nuclear DNA synthesis.
Next, we examined L1 rates in open chromatin measured using 
DNase hypersensitivity and, conversely, in closed heterochromatic 
regions by analyzing K9-trimethylated histone H3 (H3K9me3)26. 
When adjusting for the confounding effects of L1 motif content and 
replication time24, we found that somatic L1 events are enriched in 
open chromatin (1.27-fold in the top DNase hypersensitivity bin; 
95% confidence interval, 1.14–1.41; Fig. 2b) and depleted in hetero-
chromatin (1.72-fold, 95% confidence interval, 1.57–1.99; Fig. 2b). 
This finding differs from previous analyses, which have suggested 
that L1 insertions favored heterochomatin7—a discrepancy that we 
believe to be due to the confounding effect between heterochroma-
tin and late-replicating DNA regions, which was not addressed in 
previous analyses. We also found a negative association of L1 rate 
with features of active transcription of chromatin, characterized 
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by fewer L1 events at active promoters (1.63-fold; Supplementary 
Fig. 9c), a slight but significant reduction in L1 rates in highly 
expressed genes (1.25-fold lower; 95% confidence interval, 1.16–
1.34; Fig. 2b) and a further depletion at H3K36me3 (1.90-fold 
reduction in the highest tertile; 95% confidence interval, 1.59–2.29; 
Fig. 2b), a mark of actively transcribed regions deposited in the 
body and at the 3′ end of active genes26. Further details on these 
associations are shown in Supplementary Fig. 9c–e and described 
in the Supplementary Note.
The contribution of L1 source elements to the pan-cancer ret-
rotransposition burden. We used somatically mobilized L1 3′ 
transduction events to trace L1 activity to specific source elements7. 
This strategy revealed 124 germline L1 loci in the human genome 
that are responsible for most of the genomic variation generated by 
retrotransposition in the PCAWG dataset7,21 (Supplementary Table 
5). To our knowledge, 52 of these loci represent previously unre-
ported source elements in human cancer21. We analyzed the relative 
contribution of individual source elements to retrotransposition 
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Fig. 1 | Landscape of somatic retrotransposition across human cancers. a) Number of somatic retrotransposition events identified in 2,954 cancer 
genomes across six categories: solo-L1, L1-mediated transductions (TD), L1-mediated rearrangements (RG), Alu, SVA and pseudogenes (PSD). b, Left, 
circos plot showing a head-and-neck tumor (Head-SCC) with high retrotransposition rate (638 somatic events). Right, a single pancreatic adenocarcinoma 
sample harboring around 26% (70 out of 274) of all processed pseudogenes identified in the PCAWG cohort. Chromosome ideograms are shown around 
the outer ring with individual rearrangements represented as arcs; colors match the type of rearrangement. c, For 31 PCAWG cancer types with sample 
size of n ≥ 15, data show the proportion of tumor samples with >100 (red), 10–100 (orange), 1–10 (yellow) and 0 (gray) somatic retrotranspositions. The 
number of samples analyzed for each tumor type is shown in parentheses. Retrotransposition enrichment or depletion for each tumor type together with 
the level of significance (zero-inflated negative binomial regression) is shown. *P < 0.05, **P < 0.01. NA, not applicable. d, Distribution of retrotransposition 
events per sample across the four tumor types significantly enriched in somatic retrotranspositions; the remaining tumors are grouped into ‘Other’. The 
number of samples from each group is shown in parentheses; point, median; box, 25th to 75th percentiles (interquartile range); whiskers, data within 
1.5× the interquartile range. P values indicate significance from a two-tailed Mann–Whitney U-test. The y axis is shown on a logarithmic scale. e, For the 
same four tumor types in d, the fraction of structural variants (SV) belonging to six classes is shown: mobile element insertions (MEI), deletions (DEL), 
duplications (DUP), translocations (TRANS), head-to-head inversions (H2HINV) and tail-to-tail inversions (T2TINV). The total number of structural 
variants per cancer type is indicated on the right side of the panel.
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burden across cancer types, and found that retrotransposition 
is generally dominated by five hot-L1 source elements that alone 
give rise to half of all somatic transductions (Fig. 3a). This analy-
sis revealed a dichotomous pattern of hot-L1 activity, with source 
elements that we have termed Strombolian and Plinian, given their 
similarity to these two types of volcanoes (Fig. 3b). Strombolian 
source elements are relatively indolent and produce small numbers 
of retrotranspositions in individual tumor samples, although they 
are often active and contribute substantially to overall retrotrans-
position in the PCAWG dataset. By contrast, Plinian elements are 
rarely active across tumors, but in these isolated cases, their activity 
is fulminant, causing large numbers of retrotranspositions.
At the individual tumor level, although we observed that the 
number of active source elements in a single cancer genome varied 
from 1 to 22, typically only 1 to 3 loci were operative (Fig. 3c). There 
is a correlation between somatic retrotranspositions and the number 
of active germline L1 source elements among PCAWG samples (Fig. 
3d); this is likely one of the factors that explains why esophageal 
adenocarcinoma, lung and head-and-neck squamous carcinoma 
account for higher retrotransposition rates—in these three tumor 
types we also observed higher numbers of active germline L1 loci 
(Fig. 3c). Occasionally, somatic L1 integrations that retain their full 
length may also act as a source for subsequent somatic retrotrans-
position events7,27, and may reach high activity rates, leading them 
to dominate retrotransposition in a given tumor. For example, in a 
remarkable head-and-neck tumor sample, SA197656, we identified 
one somatic L1 integration at 4p16.1 that then triggered 18 trans-
ductions from its new site, with the next most active element being a 
germline L1 locus at 22q12.1, which accounted for 15 transductions 
(Supplementary Table 5).
Genomic deletions mediated by somatic L1 retrotransposition. 
In cancer genomes with high somatic L1 activity rates, we observed 
that some L1 retrotransposition events followed a distinctive pat-
tern that consisted of a single cluster of reads, associated with copy-
number loss, for which the mates unequivocally identified one 
extreme of a somatic L1 integration with, apparently, no local, recip-
rocal cluster that supported the other extreme of the L1 insertion 
(Fig. 4a). Analysis of the associated copy-number changes identified 
the missing L1 reciprocal cluster at the far end of the copy-number 
loss, indicating that this pattern represents a deletion that occurred 
in conjunction with the integration of an L1 retrotransposon (Fig. 
4b; see the Supplementary Note for additional information on how 
to interpret the paired-end mapping data from this and other fig-
ures). These rearrangements—called L1-mediated deletions—have 
been observed to occur somatically with engineered L1s in cultured 
human cells16,17 and naturally in the brain18, and are most likely the 
consequence of an aberrant mechanism of L1 integration.
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Accessible chromatin is measured through DNase hypersensitivity. c, L1 insertion density, using kernel density estimate (KDE), along the replication timing 
spectrum. DNA replication timing is expressed on a scale from 80 (early) to 0 (late).
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We developed specific algorithms to systematically iden-
tify L1-mediated deletions, and applied these methods across all 
PCAWG tumors. We identified 90 somatic events that matched 
the patterns described above, causing deletions of different size, 
which ranged in size from around 0.5 kb to 53.4 Mb (Fig. 4c and 
Supplementary Table 6). The reconstruction of the sequence at 
the breakpoint junctions in each case supports the presence of an 
L1-element—or L1-transduction—sequence and its companion 
polyadenylate tract, indicative of passage through an RNA interme-
diate. No target site duplication was found, which is also the typi-
cal pattern for L1-mediated deletions17. One potential mechanism 
for these events is that a molecule of L1 cDNA pairs with a distant 
3′ overhang from a pre-existing double-strand DNA break gener-
ated upstream of the initial integration site, and the DNA region 
between the break and the original target site is subsequently 
removed by aberrant repair17 (Fig. 4d). Indeed, in 75% (47 out of 63) 
of L1-mediated deletions with a 5′-end breakpoint characterized to 
base-pair resolution, the analysis of the sequences at the junction 
revealed short (1–5 bp long, with median at 3 bp) microhomologies 
between the pre-integration site and the 5′ L1 sequence integrated 
right there (Supplementary Table 6). Furthermore, we found 14% 
(9 out of 63) instances in which short insertions (1–33 bp long, with 
median at 9 bp) are found at the 5′-breakpoint junction of the inser-
tion. Both signatures are consistent with a non-homologous end-
joining mechanism28, or other type of microhomology-mediated 
repair, for the 5′-end attachment of the L1 cDNA to a 3′ overhang 
from a pre-existing double-strand DNA break located upstream. 
L1-mediated deletions in which microhomologies or insertions are 
not found may follow alternative models17,29–31.
To confirm that these rearrangements are mediated by the 
integration of a single intervening retrotransposition event, we 
explored the PCAWG dataset for somatic L1-mediated deletions in 
which the L1 sequences at both breakpoints of the deletion could 
unequivocally be assigned to the same L1 insertion. These include 
small deletions and associated L1 insertions that were shorter 
than the library size, allowing sequencing read pairs to overlay the 
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Fig. 3 | The dynamics of L1 source-element activity in human cancer. a, The total number of transductions identified for each cancer type is shown as a 
blue-colored scale. The sample size for each tumor type is shown in parentheses. Contribution of each source element is defined as the proportion of the 
total number of transductions from each cancer type that is explained by each source locus. Only the top ten contributing source elements are shown, 
while the remaining are grouped into the category ‘Other’. b, Two extreme patterns of hot-L1 activity, Strombolian (blue) and Plinian (red), were identified. 
Dots show the number of transductions promoted by each source element in a given tumor sample. Arrows highlight violent eruptions (that is, strong 
peaks of somatic activity) in particular samples. c, Number of active germline L1 source elements per sample, across cancer types with source element 
activity. A source element is considered to be active in a given sample if it promotes at least one transduction. The enrichment or depletion of the number 
of active source elements for each tumor type together with the level of significance (zero-inflated negative binomial regression) is shown. *P < 0.05, 
**P < 0.01. The number of samples analyzed for each tumor type is shown in parentheses. d, Correlation between the number of somatic L1 insertions and 
the number of active germline L1 source elements in PCAWG samples. Each dot represents a tumor sample and colors match cancer types. Sample sizes 
(n), together with Spearman’s ρ and P values are shown above the panel.
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entire structure. For example, in a lung tumor sample, SA313800, 
we identified a deletion involving a 1-kb region of 19q12 with 
hallmarks of being generated by an L1 element (Fig. 4e). In this 
rearrangement, we found two different types of discordant read 
pairs at the deletion breakpoints: one cluster that supported the 
insertion of an L1 element and a second that spanned the L1 event 
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Fig. 4 | The hallmarks of somatic L1-mediated deletions revealed by copy-number and paired-end mapping analysis. a, In esophageal adenocarcinoma 
sample SA528802, we found a single cluster of reads on chromosome X, which is associated with one breakpoint of a copy-number loss, and for which 
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Model of L1-mediated deletion. The integration of an L1 mRNA starts with L1-endonuclease cleavage promoting a 3′ overhang for reverse transcription. 
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chromosome 7 causes a 2.5-kb deletion, which is supported by two clusters of discordant read pairs for which the mates map onto the transduced region 
of chromosome 7.
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and supported the deletion. Another type of L1-mediated deletion 
that could unequivocally be assigned to a single L1 insertion event 
is represented by those deletions generated by the integration of 
orphan L1 transductions. These transductions represent frag-
ments of unique DNA sequence located downstream of an active 
L1 locus, which are mobilized without the companion L1 (refs. 7,15). 
For example, in one esophageal tumor sample, SA528932, we 
found a deletion of 2.5 kb on chromosome 3 mediated by the 
orphan transduction of a sequence downstream of an L1 locus on 
chromosome 7 (Fig. 4f).
Owing to the unavailability of PCAWG DNA specimens, we 
performed a validation of 16 additional somatic L1-mediated 
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deletions that were identified by TraFiC-mem in two head-
and-neck cancer cell lines with high retrotransposition rates, 
NCI-H2009 and NCI-H20877. We carried out two independent 
validation approaches, including PCR followed by single-mol-
ecule sequencing of amplicons, and Illumina whole-genome 
sequencing using mate-pair libraries with long insert size (3 kb 
and 10 kb). The results confirmed the somatic status of the rear-
rangements and a single L1-derived retrotransposition as the 
cause of the associated copy-number loss (Supplementary Figs. 
10–12 and Supplementary Table 7).
Analysis of L1 3′-extreme insertion breakpoint sequences from 
L1-mediated deletions found in the PCAWG dataset revealed that 
82% (74 out of 90) of the L1 events that caused deletions prefer-
entially inserted into sequences that resemble L1-endonuclease 
consensus cleavage sites (for example, 5′-TTTT/A-3′ and related 
sequences32) (Supplementary Table 6). This confirms that the L1 
machinery, through a target-primed reverse-transcription mecha-
nism, is responsible for the integration of most of the L1 events that 
cause neighboring DNA loss32. Notably, in 16% (14 out of 90) of 
the events endonucleotidic cleavage occurred at the phosphodi-
ester bond between a T and G instead of between the standard T 
and A site. In addition, we observed 8% (7 out of 90) instances in 
which the endonuclease motif was not found and the integrated ele-
ment was truncated at both the 5′ and 3′ ends, suggesting that a 
small fraction of L1-associated deletions are the consequence of an 
L1-endonuclease-independent insertion mechanism30–32. Whatever 
mechanism of L1 integration is effective in each case, taken together, 
these data indicate that the somatic integration of L1 elements 
induces the associated deletions.
Megabase-size L1-mediated deletions cause loss of tumor-
suppressor genes. Most L1-mediated deletions ranged from a 
few hundred to thousands of base pairs, although occasionally 
megabase-long regions of a chromosome were deleted (Fig. 4c and 
Supplementary Table 6). For example, in esophageal tumor sample 
SA528901, we found a 45.5-Mb interstitial deletion that involved 
the p31.3–p13.3 regions of chromosome 1 (Fig. 5a), in which both 
breakpoints of the rearrangement showed the hallmarks of a dele-
tion mediated by integration of an L1 element. Here, the L1 ele-
ment is 5′ truncated, which generated a small L1 insertion, allowing 
a fraction of the sequencing read pairs to span both breakpoints of 
the rearrangement. This unequivocally supports the model that the 
observed copy-number change is indeed a deletion mediated by ret-
rotransposition of an L1 element. Similarly, in a lung tumor sam-
ple, SA313800, we found an interstitial L1-mediated deletion that 
induced the loss of 51.1 Mb from chromosome X, which included 
the centromere (Fig. 5b).
L1-mediated deletions were, on occasion, driver events and 
caused the loss of tumor-suppressor genes. In esophageal tumor 
sample SA528932, the integration of an L1 transduction from chro-
mosome 7p12.3 to the short arm of chromosome 9 caused a 5.3-Mb 
clonal deletion that involved the 9p21.3–9p21.2 region. This led to the 
loss of one copy of a key tumor-suppressor gene, CDKN2A (Fig. 5c), 
which is deleted in many cancer types including esophageal 
tumors33–36. Notably, the sequencing data revealed a somatic trans-
duction that arose from this L1 element at its new insertion site, 
demonstrating that L1 events that promote deletions can be com-
petent for retrotransposition (Supplementary Fig. 13). In a second 
esophageal tumor sample, SA528899, an L1 element integrated into 
chromosome 9 promoted an 8.6-Mb clonal deletion that encom-
passes the 9p22.1–9p21.1 region that removes one copy of the same 
tumor-suppressor gene, CDKN2A (Fig. 5d). Thus, L1-mediated 
deletions have clear oncogenic potential.
L1 retrotransposition generates other types of structural varia-
tion in human tumors. Somatic retrotransposition can also be 
involved in mediating or repairing more complex structural vari-
ants. In one esophageal tumor sample, SA528896, two separate 
L1-mediated structural variants were present within a complex clus-
ter of rearrangements (Fig. 6a). In the first, an L1 transduction from 
a source element on chromosome 14q23.1 bridged an unbalanced 
translocation from chromosome 1p to 5q. A second somatic ret-
rotransposition event bridged from chromosome 5p to an unknown 
part of the genome, completing a large interstitial copy-number loss 
on chromosome 5 that involves the centromere. This case suggests 
that retrotransposon transcripts and their reverse-transcriptase 
machinery can mediate breakage and repair of complex dsDNA 
breaks, spanning two chromosomes.
To explore this further, we identified single-L1 clusters with 
no reciprocal cluster in the cancer cell lines that were sequenced 
by using mate pairs with 3 kb and 10 kb inserts. Such events may 
correspond to hidden genomic translocations leading to the link-
age of two different chromosomes, in which L1 retrotransposition 
is involved. One of the samples, NCI-H2087, showed translocation 
breakpoints at 1q31.1 and 8q24.12, both of which had the hallmarks 
of L1-mediated deletions, for which the mate-pair sequencing data 
identified an orphan L1 transduction from chromosome 6p24 that 
bridged both chromosomes (Fig. 6b). The configuration has also 
been confirmed by using long-read single-molecule sequencing 
(Supplementary Fig. 11). This interchromosomal rearrangement is 
likely mediated by the aberrant operation of L1-integration mecha-
nism, in which the L1-transduced cDNA is wrongly paired with a 
second 3′ overhang from a pre-existing double-strand break gener-
ated in a second chromosome32 (Fig. 6c).
We also found evidence that L1 integrations can cause dupli-
cations of large genomic regions in human cancer. In esophageal 
tumor sample SA528848 (Fig. 7a), we identified two indepen-
dent read clusters that support the integration of a small L1 event, 
coupled with a coverage drop at both breakpoints. Copy-number 
analysis revealed that the two L1 clusters demarcate the boundar-
ies of a 22.6-Mb duplication that involves the 6q14.3–q21 region, 
suggesting that the L1 insertion could be the cause of such rear-
rangement by bridging sister chromatids during or after DNA rep-
lication (Fig. 7b). The analysis of the rearrangement data at the 
breakpoints identified read pairs that traverse the length of the L1 
insertion breakpoints, and the L1-endonuclease motif is the L1 
Fig. 7 | Somatic L1 integration promotes duplications of megabase-scale regions in human cancers. a, In esophageal adenocarcinoma sample SA528848, 
we found a 22.6-Mb tandem duplication on the long arm of chromosome 6. The analysis of the sequencing data at the boundaries of the rearrangement 
breakpoints reveals two clusters of discordant read pairs for which the mates support the involvement of an L1 event. Because the L1 element was shorter 
than the library size, we also found two reciprocal clusters that aligned 22.6 Mb apart on the genome and in opposite orientation, spanning the insertion 
breakpoints and confirming the tandem duplication. An L1-endonuclease 5′-TTT/A-3′ degenerate motif was found. b, Large direct tandem duplications 
can be generated if the cDNA (−) strand invades a second 3′ overhang from a pre-existing double-strand break that occurred on a sister chromatid, and 
downstream to the initial integration site locus. c, In lung tumor sample SA313800, a small L1 insertion causes a 79.6-Mb duplication of the 14q arm 
through the induction of a fold-back inversion rearrangement. The analysis of the sequencing data at the breakpoint revealed two clusters of discordant 
read pairs (multi-colored reads) with the same orientation, aligning close together (5.5 kb apart) and demarcating a copy-number change for which the 
sequencing density is much greater on the right half of the rearrangement than the left. Both clusters of multi-colored reads support the integration of an 
L1. d, L1-mediated fold-back inversion model.
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3′ insertion breakpoint, both confirming a single L1 event as the 
cause of a tandem duplication (Fig. 7a). Notably, this duplication 
increases the copy number of the cyclin C gene, CCNC, which is 
dysregulated in some tumors37.
L1-mediated rearrangements can induce breakage–fusion–bridge 
cycles that trigger oncogene amplification. L1 retrotranspositions 
can also induce genomic instability by triggering breakage–fusion–
bridge cycles. This form of genetic instability starts with end-to-end 
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14q that demarcates a copy-number change that involves a 79.6-
Mb amplification of the 14q arm. Analysis of the sequencing data 
at the breakpoint revealed two discordant read clusters with the 
same orientation, which are 5.5 kb apart and support the integra-
tion of an L1. Both discordant clusters demarcate an increment of 
the sequencing coverage, for which the density is much greater in 
the right cluster. The only genomic structure that can explain this 
fusion of broken sister chromatids, and lead to a dicentric chromo-
some that forms an anaphase bridge during mitosis. Classically, the 
end-to-end chromosome fusions are thought to arise from telomere 
attrition38–40. We found, however, that somatic retrotransposition 
can induce the first inverted rearrangement that generates end-to-
end fusion of sister chromatids. In lung tumor sample SA313800 
(Fig. 7c), we found a small L1 event inserted on chromosome 
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align close together and in the same orientation, which demarcate a change in copy number; this is a distinctive pattern of a fold-back inversion42,43, a 
rearrangement typically found to be associated with breakage–fusion–bridge (BFB) repair. In this fold-back inversion, the coverage shows much greater 
density on the right half of the rearrangement than the left, indicating that the abnormal chromosome is folded back on itself leading to duplicated 
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megabase-scale regions of a chromosome that may involve centro-
meres and telomeres. It is likely that the majority of such genomic 
rearrangements would be harmful for a cancer clone. However, 
occasionally, L1-mediated deletions may promote cancer-driving 
rearrangements that involve the loss of tumor-suppressor genes 
and/or the amplification of oncogenes, representing another mech-
anism by which cancer clones acquire new mutations that help them 
to survive and grow. We expect that structural variants induced by 
somatic retrotransposition in human cancer are more frequent than 
we could unambiguously characterize here, given the constraints 
on the fragment sizes of paired-end sequencing libraries. Long-
read sequencing technologies should be able to provide a more 
comprehensive picture of how frequent such events are. Relatively 
few germline L1 loci in a given tumor, typically one to three copies, 
are responsible for such marked structural remodeling. Given the 
role that these L1 copies may have in some cancer types, this work 
underscores the importance of characterizing cancer genomes for 
patterns of L1 retrotransposition.
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are bridged by an L1 retrotransposition in head-to-head (inverted) 
orientation (Fig. 7d).
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(Fig. 8a). Copy-number data analysis showed that this L1 inser-
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an insertion event in the reference genome. However, the method differs from 
standard MEI calling to which the read mates map, as in this case mates are 
required to map to exons that belong to the same source protein-coding gene in 
GENCODE v.19. To avoid misclassification with standard genomic rearrangements 
that involve coding regions, we use MEIBA—described above—to reconstruct 
the insertion breakpoint junctions looking for hallmarks of retrotransposition, 
including the poly(A) tract and duplication of the target site. Candidate insertions 
without a poly(A) tail were discarded.
Identification of L1-mediated deletions. Independent read clusters, identified with 
TraFic-mem, supporting an L1 event (that is, clusters of discordant read pairs 
with no apparent reciprocal cluster within the proximal 500 bp, and for which 
the mates support a somatic L1 retrotransposition event) were interrogated 
for the presence of an associated change in copy number in its proximity. In 
brief, we looked for copy-number loss calls from the PCAWG Evolution and 
Heterogeneity Working Group for which the following conditions were fulfilled: 
(1) the upstream breakpoint matches an independent L1 cluster in positive 
orientation, (2) the corresponding downstream breakpoint, if any, from the same 
change in copy number matches an independent L1 cluster in negative orientation, 
and (3) the reconstruction of the structure of the putative insertion causing the 
deletion is compatible with one-single retrotransposition event. We used MEIBA 
(Supplementary Note) to reconstruct the insertion breakpoint junctions to confirm 
the ends of the events and identify hallmarks of retrotransposition, including the 
poly(A) tract and duplication of the target site.
An additional strategy was used for L1-mediated deletions that were shorter 
than 100 kb. Read-depth drops in the proximity of independent clusters were 
detected by, first, normalizing the read depth on each side of the cluster, using the 
matched normal sample as a reference. Then, the ratio between the normalized 
read depth on both sides of the cluster was computed for windows of 200–5,000 bp. 
Adjacent buffer regions of 300 bp on each side of the cluster were omitted from 
read-depth calculations to avoid false positives caused by sequence repeats. Pairs 
of independent reciprocal (positive–negative) clusters were selected such that: 
(1) both clusters were located less than 100 kb apart, (2) a potential drop in the 
read-depth ratio was identified, extending from the positive cluster to the negative 
cluster, and (3) the reconstruction of the structure of the putative insertion that 
caused the deletion was compatible with a single L1 event. For each cluster pair, 
the continuity and reliability of the copy-number drop was assessed by measuring 
the normalized read-depth ratio between non-overlapping 500-bp windows that 
spanned the region between the positive and negative clusters (that is the putative 
deletion) and windows upstream and downstream of the positive and negative 
clusters, respectively. The significance of each read-depth ratio drop was estimated 
nonparametrically using a null distribution of normalized read-depth ratios. This 
distribution was obtained for each tumor sample by randomly sampling 100,000 
genomic locations (from copy-number segments showing the predominant copy 
number), and calculating read-depth ratios between both sides of each position. 
Nonparametric P values were calculated by comparing observed read-depth ratios 
with this null distribution, and adjusted using the Benjamini–Hochberg correction. 
Two cluster groups were produced: tier 1, pairs of reciprocal clusters with both 
clusters that had P < 0.1, and tier 2, pairs of reciprocal clusters with only one of 
both clusters having P < 0.1.
Retrotransposition rate enrichment and depletion across tumor types. For each tumor 
type with a minimum sample size of 15, we assessed whether it was enriched or 
depleted in retrotransposition compared to the overall retrotransposition burden 
using zero-inflated negative binomial regression, as implemented in the zeroinfl 
function of the pscl R package. This type of model takes into account the excess 
of zeros and the overdispersion that is present in this dataset. The MEI counts per 
sample were regressed on a binary factor that expressed whether they belonged 
to that particular type of cancer or to any other cancer type. On each regression, 
the magnitude and sign of the z-score indicates the effect size and directionality of 
the association. More specifically, positive z-scores indicate that a higher number 
of counts in the samples belongs to a particular cancer type compared with the 
rest (enrichment), whereas negative scores indicate a lower number of counts 
(depletion). Each z-score is accompanied by its P value to indicate the level of 
statistical significance.
Association between mutation in tumor-suppressor genes and retrotransposition and 
structural variantion rates. To assess whether the disruption of a particular tumor-
suppressor gene was associated with a high level of retrotransposition, we used 
the whole-genome panorama of cancer driver events per sample produced by the 
PCAWG Drivers and Functional Interpretation Working Group21. This panorama 
includes coding and non-coding SNVs, insertions and deletions, copy-number 
alterations, structural variants and potentially predisposing germline variants. For 
each tumor-suppressor gene in the Cancer Gene Census database with mutational 
data, we stratified the samples into two groups—mutated tumor-suppressor genes 
and non-mutated tumor-suppressor genes. Then, we compared the distribution 
of MEI counts between both groups using a Mann–Whitney U-test to identify 
significant differences. P values were corrected for multiple testing using the 
Benjamini–Hochberg procedure. Adjusted P < 0.05 were considered significant. 
Methods
Pan-cancer datasets. Whole-genome sequencing dataset. We analyzed Illumina 
whole-genome paired-end sequencing reads (100–150 bp) from 2,954 tumors and 
matched normal samples across 38 cancer types21. On the basis of the robustness 
of the retrotransposition calls (false discovery rate of <5%), we opted to retain 
all samples that were preliminarily excluded by the PCAWG Consortium21, as 
they were excluded from SNV and structural variation analyses on the basis 
of read direction biases from PCR artifacts or poor sequence quality, but were 
not found to be problematic for retrotransposition analysis. For the majority of 
donors, the tumor specimens consisted of a fresh frozen sample, whereas the 
normal specimens consisted of a blood sample. Most of the tumor samples came 
from treatment-free primary cancers, although there was also a small number of 
donors with multiple samples of primary, metastatic and/or recurrent tumors. The 
average coverage was 30 reads per genome for normal samples, whereas tumor 
samples had a bimodal coverage distribution with maxima at 38 and 60 reads per 
bp (Supplementary Fig. 1 and Supplementary Table 1). BWA-mem44 v.0.7.8-r455 
was used to align each tumor and normal sample to human reference build 
GRCh37. Additional technical details of the sequencing metrics are provided in 
Supplementary Table 1 and in the PCAWG lead paper21. The Ethics oversight for 
the PCAWG protocol was undertaken by the TCGA Program Office and the Ethics 
and Governance Committee of the ICGC.
Transcriptome dataset. About half of the donors (1,188) with whole-genome data 
in PCAWG had at least one tumor specimen with whole transcriptome obtained 
by RNA sequencing (RNA-seq). Mapping onto the reference was carried out using 
two independent read aligners, STAR45 v.2.4.0i, two-pass and TopHat2 (ref. 46) 
v.2.0.12. Gene expression was quantified with HTSeq47 v.0.6.1p1 and consensus 
normalized expression values, in fragments per kilobase of transcript per million 
mapped reads (FPKM), were obtained by averaging the expression from STAR and 
TopHat2. A more detailed description of RNA-seq data processing is provided by 
the PCAWG Integration of Transcriptome and Genome Working Group48.
Copy-number dataset. We analyzed copy-number profiles obtained by the PCAWG 
Evolution and Heterogeneity Working Group, using a consensus approach that 
combines six different state-of-the-art copy-number calling methods49. GC content 
corrected logR values were extracted using the Battenberg algorithm50, smoothed 
using a running median and transformed into copy-number space according to 
n = [(2(1 − ρ) + ψρ)2logR − 2(1 − ρ)]/ρ where ρ and ψ are consensus tumor purity and 
ploidy, respectively.
Structural variant dataset. The structural variation call set was generated by the 
PCAWG Somatic Structural Variation Working Group by merging the structural 
variant calls from four independent calling pipelines51. The merged structural 
variant calls were further required to have a consistent change in copy number.
Analysis of somatic retrotransposition. Detection of mobile element insertions 
using TraFiC-mem. BAM files from tumor and matched normal pairs were 
processed with TraFiC-mem v.1.1.0 to identify somatic mobile element insertions 
(MEIs) including solo-L1, L1-mediated transductions, Alu, SVA and ERV-K using 
Illumina paired-end mapping data. TraFiC-mem starts by identifying candidate 
somatic MEIs by analyzing discordant read pairs. In contrast to a previous 
version of the algorithm7, the new pipeline uses BWA-mem v.0.7.17 instead of 
RepeatMasker as the search engine for the identification of retrotransposon-like 
sequences in the sequencing reads. Calls obtained at this step are preliminary, 
in which MEI features are outlined and insertion coordinates represent ranges 
that surround the breakpoints. Then, a new module of TraFiC-mem, called 
MEIBA (from Mobile Element Insertion Breakpoint Analyzer), is used to identify 
the integration breakpoints to base-pair resolution and to perform a detailed 
characterization of MEI features, including structure, subfamily assignment and 
insertion site annotation. TraFiC-mem is illustrated in Supplementary Fig. 3. 
Detailed information about the pipeline is provided in the Supplementary Note.
Identification of germline and somatic L1 source elements. Because L1-mediated 
transductions are defined by the retrotransposition of unique, non-repetitive 
genomic sequences, we can unambiguously identify the L1 source element from 
which they derive7. The method relies on the detection of unique DNA regions 
retrotransposed somatically elsewhere in the cancer genome from a single locus 
that matches the 10-kb downstream region of a reference full-length L1 element 
or a putative non-reference polymorphic L1 element detected by TraFiC-mem 
across the matched normal samples in the PCAWG cohort21. When transduced 
regions were derived from the downstream region of a putative L1 event present 
in the tumor genome but not in the matched normal genome, we catalogued these 
elements as somatic L1 source loci.
Identification of processed pseudogene insertions. An additional separate module 
of TraFiC-mem was implemented for the identification of somatic insertions 
of processed pseudogenes. The method relies on the same principle as for the 
identification of somatic MEI events, through the detection of two reciprocal 
clusters of discordant read pairs, namely positive and negative, that supports 
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To create the artificial, tumoral genome, 10,000 L1 insertion breakpoints—
including solo-L1, partnered and orphan transductions—were randomly 
distributed in the standard reference genome using BedTools v.2.25.0, 
of which 9,227 were inserted out of un-sequenced gaps. Then, ART55 
(v.MountRainier-2016-06-05) was used to generate paired-end read sequencing 
data for both the standard and the artificial reference genomes to a 38× coverage. 
The simulation FASTQ files were aligned into the standard reference genome with 
BWA-mem56 v.0.7.17. Reads from the normal and tumor BAM files were randomly 
subsampled and merged with samtools v.1.7 at three distinct proportions to also 
produce tumor samples with 25%, 50% and 75% clonalities. After that, the four 
possible tumor and matched normal pairs were processed with TraFiC-mem to 
call MEIs. For each clonality, the identified MEIs were compared with the list of 
simulated MEIs to compute the number of true-positive (TP), false-positive (FP), 
true-negative (TN) and false-negative (FN) calls. Finally, precision and recall were 
computed as follows: Precision = TP/(TP + FP); Recall = TP/(TP + FN).
Validation of TraFiC-mem calls using single-molecule sequencing. We performed 
validation of 308 putative somatic retrotranspositions identified with TraFiC-
mem in one cancer cell line (NCI-H2087) with high retrotransposition rate, and 
absent in the matched normal cell line (NCI-BL2087) derived from blood, by 
single-molecule sequencing using Oxford Nanopore technology. Genomic DNA 
was sheared to 10-kb fragments using Covaris g-TUBEs, and cleaned with 0.4× 
Ampure XP Beads. After end-repairing and dA-tailing using the NEBNext End 
Repair/dA-tailing module (NEB), whole-genome libraries were constructed with 
the Oxford Nanopore Sequencing 1D ligation library prep kit (SQK-LSK108, 
Oxford Nanopore Technologies). Genomic libraries were loaded on MinION R9.4 
flowcells. We used the Oxford Nanopore basecaller Albacore v.2.0.1 to generate 
fastq files. After quality filtering of the fastq files and read trimming of the data 
with Porechop v.0.2.3, we used minimap2 (ref. 57) v.2.10-r764-dirty to map 
sequencing reads onto the hs37d5 reference genome. Sequencing coverages were 
8.2× (NCI-BL2087) and 9.17× (NCI-H2087), and average read sizes of mapped 
reads were ~4.5 kb (NCI-BL2087) and ~11 kb (NCI-H2087). After obtaining the 
whole-genome BAM files for each of the 308 putative somatic retrotransposition 
calls identified with TraFic-mem, we interrogated the long-read tumor BAM file 
to find reads that validated the event. MEIs supported by at least one Nanopore 
read in the tumor and absent in the matched normal sample were considered true-
positive somatic events, while MEIs not supported by long reads in the tumor and/
or present in the matched normal were considered false-positive calls. Overall, 
we found 4.22% (13/308) false-positive events. False discovery rate (FDR) was 
estimated as follows: FDR = FP/(TP + FP).
Validation of L1-mediated rearrangements with PCR and single-molecule sequencing. 
We performed validation of 20 somatic L1-mediated rearrangements, mostly 
deletions, identified in two cancer cell lines with high retrotransposition rates 
(NCI-H2009 and NCI-H2087). We carried out PCR followed by single-molecule 
sequencing of amplicons from the two tumor cell lines and their matched normal 
samples (NCI-BL2009 and NCI-BL2087) using a MinION from Oxford Nanopore. 
PCR primers were designed to amplify three regions from each event (namely, 
5′-extreme, 3′-extreme and target sites) as shown in Supplementary Fig. 10.
Validation of L1-mediated rearrangements using mate pairs. To further validate and 
characterize L1-mediated rearrangements, we performed 10× mate-pair whole-
genome sequencing using libraries with two different insert sizes (4 kb and 10 kb), 
which can span the integrated L1 element that caused the deletion, enabling the 
validation of the involvement of L1 in the generation of such rearrangements. 
Mate-pair reads (100 nucleotides long) were aligned to the human reference 
with BWA-mem v.0.7.17. Then, for each candidate L1-mediated rearrangement, 
we searched for discordant mate-pair clusters that spanned the breakpoints and 
supported the L1-mediated event. Each event was confirmed by visual inspection 
of the BAM files using Integrative Genomics Viewer v.2.4.10.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
Somatic and germline variant calls, mutational signatures, subclonal 
reconstructions, transcript abundance, splice calls and other core data generated 
by the ICGC/TCGA PCAWG Consortium are available for download at https://
dcc.icgc.org/releases/PCAWG. Additional information on accessing the data, 
including raw read files, can be found at https://docs.icgc.org/pcawg/data/. In 
accordance with the data access policies of the ICGC and TCGA projects, most 
molecular, clinical and specimen data are in an open tier, which does not require 
access approval. To access potentially identifying information, such as germline 
alleles and underlying sequencing data, researchers will need to apply to the 
TCGA Data Access Committee (DAC) via dbGaP (https://dbgap.ncbi.nlm.nih.
gov/aa/wga.cgi?page=login) for access to the TCGA portion of the dataset, and to 
the ICGC Data Access Compliance Office (DACO; http://icgc.org/daco) for the 
ICGC portion. In addition, to access somatic SNVs derived from TCGA donors, 
researchers will also need to obtain dbGaP authorization.
This analysis was done at both the level of the individual cancer type and the level 
of pan-cancer to identify tumor-type-specific associations. We further investigated 
whether there was a TP53 dosage effect as follows: every PCAWG sample was 
classified into three groups according to TP53 mutational status, namely wild-type, 
monoallelic and biallelic driver mutation. Then, the MEI counts distribution was 
compared for all possible group pair combinations using a Mann–Whitney U-
test. The same analysis described above was applied to investigate the association 
between TP53 mutation and other types of structural variation.
Correlation between L1 insertion and structural variation rate. For each sample, 
we computed the number of MEIs, the total number of structural variants and 
the number of five different structural variant classes: deletions, duplications, 
translocations, head-to-head inversions and tail-to-tail inversions, when data were 
available. Then, the correlation between the number of MEIs and the structural 
variant burden was assessed at both the level of the individual tumor type and the 
level of the pan-cancer using a Spearman’s rank test.
Association between L1 insertion rate and genomic features. The L1 insertion rate 
was calculated as the total number of somatic L1 insertions, identified across the 
complete PCAWG cohort per 1-Mb window. The density of L1 endonuclease motifs 
was computed as the number of canonical endonuclease motifs, here defined as 
TTTT|R (where R is A or G) or Y|AAAA (where Y is C or T) per 1-Mb window. To 
study the association of L1 insertion rate with multiple variables at single-nucleotide 
resolution, we used a statistical framework based on negative binomial regression, 
as described in detail previously24, and adapted to adjust for the genome-wide 
distribution of the L1 endonuclease motif; we stratified the genome into four bins 
(0–3) by the closeness of match to the motif. Bin 0 contains dissimilar DNA motifs, 
with four or five (out of five) mismatches, encompassing 1,150 Mb. Bins 1, 2 and 3 
contain loci with three, two and at most one mismatches, encompassing 749 Mb, 
380 Mb and 114 Mb, respectively. The closer match of either of the two DNA strands 
at each locus was considered. Histone mark data and DNase hypersensitivity data 
were obtained from the Roadmap Epigenomics Consortium by averaging the fold-
enrichment signal across eight cell types and processed by stratifying into four 
genomic bins as described previously24: bin 0 contains regions with below-baseline 
signal (fold enrichment versus input <1), while bins 1–3 are approximately equal-
sized bins that cover the remainder of the genome. RNA-seq data from Roadmap 
were processed by averaging across eight cell types; bin 0 contains non-expressed 
genes (FPKM = 0) and intergenic DNA not listed as expressed, while bins 1–3 
included genes with up to 0.59, 5.68 and above 5.68 FPKM, respectively. Replication 
time was averaged across the eight ENCODE cell types and divided into four equal-
sized genomic bins, where bin 0 is latest and bin 3 is earliest replicating. Essential 
genes were estimated from CRISPR screens in cell lines52. All enrichment scores 
shown compare bins 1–3 for a particular feature (replication time, histone marks, 
gene expression, L1 motif) versus bin 0 of the same feature. Bin 0 therefore always 
has log enrichment = 0 by definition and is not shown on plots. The analyses were 
restricted to regions of the genome with perfect CRG75 alignability.
Impact of retrotransposition insertions on gene expression. To study the 
transcriptional impact of a somatic L1 insertion within COSMIC cancer genes 
and promoters, we used RNA-seq data to compare gene-expression levels in 
samples with and without somatic L1 insertion. For each somatic L1 insertion 
within a cancer gene or promoter, we compared the gene FPKM between the 
sample having the insertion (study sample) and the remaining samples of the same 
tumor type (control samples). Using the distribution of gene-expression levels in 
control samples, we calculated the normalized gene expression differences using a 
Student’s t-test. To overcome the problems due to multiple testing, false discovery 
rate–adjusted P values (q values) were calculated using the Benjamini–Hochberg 
procedure, and adjusted P < 0.1 was considered to be significant.
Analysis of processed pseudogene expression. We analyzed the PCAWG RNA-seq 
data to identify and characterize the transcriptional consequences of somatic 
integrations of processed pseudogenes (PSD). We interrogated RNA-seq split reads 
and discordant read pairs, looking for chimeric retrocopies that involved PSDs 
and target genomic regions. For each PSD insertion somatic call, we extracted all 
of the RNA-seq reads (when available), mapping the source gene and the insertion 
target region, together with the RNA-seq unmapped reads for the corresponding 
sample. Then, we used these reads as a query in BLASTn53 v.2.7.1 searches against 
a database that contained all isoforms of the source gene described in RefSeq54, 
together with the genomic sequence ranging from −5 kb to +5 kb around the 
PSD integration site. Finally, we looked for RNA-seq discordant read pairs and/
or RNA-seq clipped reads that supported the joint expression of PSD and target 
site. Only read pairs with one of the mates aligned to the host gene mRNA with 
>98% identity were considered. All expression signals were confirmed by visual 
inspection with Integrative Genomics Viewer v.2.4.10.
Validation of somatic retrotransposition algorithms. In silico validation of 
TraFiC-mem. To evaluate the precision and recall of our algorithm TraFiC-mem, 
we reanalyzed a mock cancer genome into which we had previously seeded known 
somatic retrotransposition events at different levels of tumor clonality7.  
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Data collection Data and metadata were collected from International Cancer Genome Consortium (ICGC) consortium members using custom software 
packages designed by the ICGC Data Coordinating Centre. The general-purpose core libraries and utilities underlying this software have 
been released under the GPLv3 open source license as the "Overture" package and are available at https://www.overture.bio. Other data 
collection software used in this effort, such as ICGC-specific portal user interfaces, are available upon request to contact@overture.bio. 
Data analysis Somatic mobile element insertions (MEIs) were identified with TraFiC-mem v1.2.0 (https://gitlab.com/mobilegenomesgroup/TraFiC). 
MEIs target genomic regions were annotated using ANNOVAR v2016-02-01 and GENCODE v19 annotation. Oxford Nanopore 
Technologies (ONT) sequencing data was generated and processed using these packages: MinKNOW v18.01.6; Albacore v2.0.1; Porechop 
v0.2.3; minimap2 v2.10-r764-dirty74; Samtools v1.7. Simulated data containing MEIs were realigned using biobambam v2.0.25 and BWA-
mem v0.7.17. 
 
The workflows executing core WGS alignment, QC and variant-calling software are packaged as executable Dockstore images and 
available at: https://dockstore.org/search?labels.value.keyword=pcawg&searchMode=files. Individual software components are as 
follows: BWA-MEM v0.78.8-r455; DELLY v0.6.6; ACEseq v1.0.189; DKFZ somatic SNV workflow v1.0.132-1; Platypus v0.7.4; ascatNgs 
v1.5.2; BRASS v4.012; grass v1.1.6; CaVEMan v1.50; Pindel v1.5.7; ABSOLUTE/JaBbA v1.5; SvABA 2015-05-20; dRanger 2016-03-13; 
BreakPointer 2015-12-22; MuTect v1.1.4; MuSE v1.0rc; SMuFIN 2014-10-26; OxoG 2016-4-28; VAGrENT v2.1.2; ANNOVAR v2014Nov12; 
VariantBAM v2017Dec12; SNV-Merge v2017May26; SV-MERGE v2017Dec12; DKFZ v2016Dec15. 
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. 
We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
Somatic mobile element insertion calls can be found in Synapse at https://www.synapse.org/ with accession code syn21052009 and in DCC Portal at https://
dcc.icgc.org/releases/PCAWG/retrotransposition 
 
WGS somatic and germline variant calls, mutational signatures, subclonal reconstructions, transcript abundance, splice calls and other core data generated by the 
ICGC/TCGA Pan-cancer Analysis of Whole Genomes Consortium are available for download at https://dcc.icgc.org/releases/PCAWG. Additional information on 
accessing the data, including raw read files, can be found at https://docs.icgc.org/pcawg/data/. In accordance with the data access policies of the ICGC and TCGA 
projects, most molecular, clinical and specimen data are in an open tier which does not require access approval. To access potentially identification information, 
such as germline alleles and underlying sequencing data, researchers will need to apply to the TCGA Data Access Committee (DAC) via dbGaP (https://
dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login) for access to the TCGA portion of the dataset, and to the ICGC Data Access Compliance Office (DACO; http://
icgc.org/daco) for the ICGC portion. In addition, to access somatic single nucleotide variants derived from TCGA donors, researchers will also need to obtain dbGaP 
authorization
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Sample size We compiled an inventory of matched tumour/normal whole cancer genomes in the ICGC Data Coordinating Centre. Most samples came 
from treatment-naïve, primary cancers, but there were a small number of donors with multiple samples of primary, metastatic and/or 
recurrent tumours. Our inclusion criteria were: (i) matched tumour and normal specimen pair; (ii) a minimal set of clinical fields; and (iii) 
characterisation of tumour and normal whole genomes using Illumina HiSeq paired-end sequencing reads.  
We collected genome data from 2,834 donors, representing all ICGC and TCGA donors that met these criteria at the time of the final data 
freeze in autumn 2014. 
Data exclusions Based on the robustness of the retrotransposition calls (false discovery rate <5%), we opted to retain all samples preliminarly excluded by the 
PCAWG Consortium, as they were excluded from single-nucleotide variants and structural variation analyses based on read direction biases 
from PCR artifacts or poor sequence quality, but were not found to be problematic for retrotransposition analysis.
Replication The core pipeline for the identification of somatic mobile element insertions, TraFiC-mem, was validated through long-read sequencing data 
analysis in one cancer cell-line with high retrotransposition rate and its matched normal sample. 295 out of 308 somatic retrotransposition 
events were confirmed through the long-reads (false discovery rate <5%). In addition, TraFiC-mem was assessed using simulated data 
containing MEIs at different levels of tumour clonality. This analysis confirmed a high precision (>99%) and a recall ranging from 90 to 94% for 
tumour clonalities from 25 to 100%, respectively.  
 
In order to evaluate the performance of each of the mutation-calling pipelines and determine an integration strategy, we performed a large-
scale deep sequencing validation experiment. We selected a pilot set of 63 representative tumour/normal pairs, on which we ran the three 
core pipelines, together with a set of 10 additional somatic variant-calling pipelines contributed by members of the SNV Calling Working 
Group. Overall, the sensitivity and precision of the consensus somatic variant calls were 95% (CI90%: 88-98%) and 95% (CI90%: 71-99%) 
respectively for SNVs. For somatic indels, sensitivity and precision were 60% (34-72%) and 91% (73-96%) respectively. Regarding SVs, we 
estimate the sensitivity of the merging algorithm to be 90% for true calls generated by any one caller; precision was estimated as 97.5% - that 
is, 97.5% of SVs in the merged SV call-set have an associated copy number change or balanced partner rearrangement.
Randomization No randomisation was performed.
Blinding No blinding was undertaken.
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Population characteristics Patient-by-patient clinical data are provided in the marker paper for the PCAWG consortium (Extended Data Table 1 of that 
manuscript). Demographically, the cohort included 1,469 males (55%) and 1,189 females (45%), with a mean age of 56 years 
(range, 1-90 years). Using population ancestry-differentiated single nucleotide polymorphisms (SNPs), the ancestry distribution 
was heavily weighted towards donors of European descent (77% of total) followed by East Asians (16%), as expected for large 
contributions from European, North American and Australian projects. We consolidated histopathology descriptions of the 
tumour samples, using the ICD-0-3 tumour site controlled vocabulary. Overall, the PCAWG data set comprises 38 distinct tumour 
types. While the most common tumour types are included in the dataset, their distribution does not match the relative 
population incidences, largely due to differences among contributing ICGC/TCGA groups in numbers sequenced. 
Recruitment Patients were recruited by the participating centres following local protocols. 
Ethics oversight The Ethics oversight for the PCAWG protocol was undertaken by the TCGA Program Office and the Ethics and Governance 
Committee of the ICGC. Each individual ICGC and TCGA project that contributed data to PCAWG had their own local 
arrangements for ethics oversight and regulatory alignment.
Note that full information on the approval of the study protocol must also be provided in the manuscript.
